This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Christina Dillmann: Innovator in Immunology
Introduction
Christina Dillmann is a prominent inventor based in Frankfurt, Germany. She has made significant contributions to the field of immunology, particularly through her innovative research on interleukin-38. Her work has implications for the treatment and prevention of autoimmune disorders.
Latest Patents
Christina Dillmann holds a patent for an N-terminally truncated interleukin-38 protein. This invention pertains to the truncated IL-38 protein, functional variants, nucleic acids, and vectors encoding the truncated peptide. The research demonstrates that IL-38 is N-terminally processed and that the truncated version acts as an antagonist of immune activation in macrophages. This discovery indicates potential therapeutic uses for the truncated cytokine in autoimmune disorders. The patent also includes pharmaceutical compositions comprising the truncated IL-38 protein and methods for screening modulators of its function.
Career Highlights
Christina Dillmann is affiliated with the Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., a leading research organization in Germany. Her work has been instrumental in advancing the understanding of immune responses and developing new therapeutic strategies.
Collaborations
Some of her notable coworkers include Michael John Parnham and Gerd Geisslinger, who have collaborated with her on various research projects.
Conclusion
Christina Dillmann's innovative research and patent contributions are paving the way for new treatments in immunology. Her work exemplifies the impact of scientific innovation on healthcare and the potential for improving patient outcomes.